Compare Amphastar Pharmaceuticals Inc (AMPH) vs Realty Income Corp (O) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Realty Income Corp — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Realty Income Corp trades at $63.24 (market cap $59.04B). The key difference: Realty Income Corp is far larger — about 71.5× Amphastar Pharmaceuticals Inc's market cap, and Realty Income Corp pays a 5.14% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | O | |
|---|---|---|
Market Cap | $826.08M | $59.04B |
Sector | Health | Real Estate |
52-Week High | $30.81 | $67.56 |
52-Week Low | $16.87 | $55.93 |
Enterprise Value | $1.22B | $88.84B |
Dividend Yield | — | 5.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Realty Income (O) trades at $63.31, up 0.22% on the day, with a bullish technical signal from moving averages and strong support at $63. The company shows robust revenue growth, reaching $5.75B in 2025, and maintains a high gross margin of 92.54%, though it has missed recent EPS estimates. Dividend payments remain consistent at $0.27 monthly, supporting income-focused strategies.
Outlook is cautiously optimistic with a consensus price target of $67.86, offering ~7% upside. Risks include rising debt levels and interest expense, but strategic expansion into data centers and high occupancy rates provide stability. Analyst sentiment is mixed with 41% buy ratings, reflecting balanced growth and valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Realty Income Corp
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →
